STOCK TITAN

Parabilis Medicines (PBLS) General Counsel details long-term option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Parabilis Medicines, Inc. General Counsel Teresa Jurgensen filed an initial ownership report showing holdings of stock options tied to the company’s common stock. She holds options covering 162,453 shares at an exercise price of $3.14 per share expiring on February 17, 2036, and options covering 214,438 shares at $1.88 per share expiring on September 4, 2034. According to the vesting schedules, 25% of one grant vested on August 1, 2025 with the balance vesting in 36 monthly installments, while the other grant vests in 48 equal monthly installments beginning on February 9, 2026, subject to her continued service.

Positive

  • None.

Negative

  • None.
Insider Jurgensen Teresa
Role General Counsel
Type Security Shares Price Value
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
Holdings After Transaction: Stock Option (right to buy) — 214,438 shares (Direct, null)
Footnotes (1)
  1. 25% of the shares subject to this option vested and became exercisable on August 1, 2025 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.
Underlying shares (grant 1) 162,453 shares Stock option at $3.14 exercise price
Exercise price (grant 1) $3.14 per share Stock Option (right to buy), expires February 17, 2036
Underlying shares (grant 2) 214,438 shares Stock option at $1.88 exercise price
Exercise price (grant 2) $1.88 per share Stock Option (right to buy), expires September 4, 2034
Vested portion (grant 1) 25% vested Vested on August 1, 2025; balance over 36 months
Vesting period (grant 2) 48 monthly installments Commencing February 9, 2026, subject to continued service
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"exercisePrice: "3.1400" and "1.8800" as the exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-02-17T00:00:00.000Z and 2034-09-04T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting in monthly installments financial
"vesting in thirty-six (36) equal monthly installments thereafter"
underlying common stock financial
"underlying_security_title: "Common Stock""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does Parabilis Medicines (PBLS) General Counsel report in this Form 3?

Parabilis Medicines General Counsel Teresa Jurgensen reports her holdings of stock options linked to common shares. The filing lists option quantities, exercise prices, expiration dates, and vesting schedules, but does not show any recent buying or selling activity.

How many Parabilis Medicines (PBLS) shares are covered by Teresa Jurgensen’s options?

Her disclosed options cover 162,453 underlying common shares in one grant and 214,438 underlying common shares in another. These figures reflect potential shares purchasable upon exercise, subject to vesting and other standard conditions described in the filing.

What are the exercise prices of the Parabilis Medicines (PBLS) options reported?

The reported stock options have exercise prices of $3.14 per share for one grant and $1.88 per share for the other. These prices represent the cost per share to acquire common stock if the options are exercised after vesting.

When do the Parabilis Medicines (PBLS) General Counsel’s options expire?

One option grant expires on February 17, 2036, and the other expires on September 4, 2034. These expiration dates define the latest possible dates by which vested options can be exercised under the terms of the grants.

How do the Parabilis Medicines (PBLS) option grants vest for the General Counsel?

For one grant, 25% of the options vested on August 1, 2025, with the remaining 75% vesting in 36 equal monthly installments. The second grant vests in 48 equal monthly installments starting February 9, 2026, contingent on continued service.

Does this Parabilis Medicines (PBLS) Form 3 show insider buying or selling?

The Form 3 primarily records existing stock option holdings and their terms, not new market trades. The summarized data show unknown transaction codes and no net share purchases or sales, indicating this filing is an initial ownership snapshot rather than a trade report.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Jurgensen Teresa

(Last)(First)(Middle)
C/O PARABILIS MEDICINES, INC.
30 ACORN PARK DRIVE, 6TH FLOOR

(Street)
CAMBRIDGE MASSACHUSETTS 02140

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026
3. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
General Counsel
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) (1)09/04/2034Common Stock214,438$1.88D
Stock Option (right to buy) (2)02/17/2036Common Stock162,453$3.14D
Explanation of Responses:
1. 25% of the shares subject to this option vested and became exercisable on August 1, 2025 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
2. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Teresa Jurgensen06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)